The Priority Review

Tag

brentuximab vedotin

1 story

  1. Clinical trials

    Seagen posts results of Phase 3 ECHELON-3 trial of brentuximab vedotin in relapsed/refractory DLBCL

    The study enrolled 240 participants and compared brentuximab vedotin plus lenalidomide and rituximab to placebo plus lenalidomide and rituximab. Results were first posted on ClinicalTrials.gov on October 21, 2026.